Platform Technology Partners Sells 200 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Platform Technology Partners reduced its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 8.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,262 shares of the biotechnology company’s stock after selling 200 shares during the period. Platform Technology Partners’ holdings in Sarepta Therapeutics were worth $275,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in SRPT. MassMutual Private Wealth & Trust FSB grew its holdings in Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 156 shares during the last quarter. Sunbelt Securities Inc. lifted its holdings in shares of Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 232 shares during the period. Huntington National Bank grew its stake in shares of Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 175 shares during the last quarter. UMB Bank n.a. increased its holdings in Sarepta Therapeutics by 105.9% in the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 197 shares during the period. Finally, Values First Advisors Inc. bought a new position in Sarepta Therapeutics during the 3rd quarter worth $59,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insider Buying and Selling

In other news, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now owns 5,880 shares in the company, valued at $738,234. This represents a 21.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Sarepta Therapeutics Stock Down 0.3 %

Sarepta Therapeutics stock opened at $111.82 on Friday. The firm has a market capitalization of $10.68 billion, a price-to-earnings ratio of 89.46 and a beta of 0.75. The firm’s fifty day moving average price is $121.12 and its two-hundred day moving average price is $126.11. Sarepta Therapeutics, Inc. has a 1-year low of $102.15 and a 1-year high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Analyst Upgrades and Downgrades

SRPT has been the topic of a number of analyst reports. Evercore ISI reduced their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Royal Bank of Canada reiterated an “outperform” rating and issued a $182.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 21st. Needham & Company LLC restated a “buy” rating and set a $202.00 price target on shares of Sarepta Therapeutics in a report on Monday, January 27th. StockNews.com downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Finally, Guggenheim increased their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $178.71.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.